Atopic Dermatitis (AD) Treatment Initiation and Monitoring
166031660316603
During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.
CASE 1
51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …
During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.
CASE 1
51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA … Continue reading "Atopic Dermatitis (AD) Treatment Initiation and Monitoring"
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c … 